List of Excipients in Branded Drug TERAZOSIN HYDROCHLORIDE ANHYDROUS

« Back to Dashboard

Generic Drugs Containing TERAZOSIN HYDROCHLORIDE ANHYDROUS

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	terazosin hydrochloride anhydrous	0378-2260	ANHYDROUS LACTOSE
Mylan Pharmaceuticals Inc	terazosin hydrochloride anhydrous	0378-2260	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	terazosin hydrochloride anhydrous	0378-2260	D&C RED NO. 28

What are the Most Frequently-Used Excipients in TERAZOSIN HYDROCHLORIDE ANHYDROUS?

# Of NDCs	Excipient
3	ANHYDROUS LACTOSE
3	CELLULOSE, MICROCRYSTALLINE
3	D&C RED NO. 28

Terazosin Hydrochloride Anhydrous Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Terazosin hydrochloride anhydrous is a mature, off-patent alpha-1 adrenergic receptor antagonist used primarily for hypertension and benign prostatic hyperplasia (BPH). The commercial opportunity is not an originator-style exclusivity play. It is a formulation, supply, lifecycle-management, and market-access opportunity focused on low-cost immediate-release tablets and capsules, dose flexibility, manufacturing reliability, and differentiated patient-use characteristics.

The active ingredient has a low-dose product profile, with marketed strengths commonly including 1 mg, 2 mg, 5 mg, and 10 mg. At these doses, excipient selection can materially affect blend uniformity, content uniformity, tablet size, dissolution, stability, and production economics.

What is the FDA regulatory status of terazosin hydrochloride anhydrous?

Terazosin hydrochloride products are approved in the United States as immediate-release oral capsules and tablets for hypertension and symptomatic BPH. Terazosin is administered once daily in many regimens, with dose escalation required because of first-dose hypotension risk.[1,2]

Attribute	Assessment
Active ingredient	Terazosin hydrochloride anhydrous
Pharmacologic class	Alpha-1 adrenergic receptor antagonist
Primary indications	Hypertension and BPH
Dosage forms	Immediate-release capsules and tablets
Typical strengths	1 mg, 2 mg, 5 mg, and 10 mg
FDA pathway for new generic products	ANDA under Section 505(j)
Reference product	Hytrin
Current commercial position	Mature generic market
Biologic or biosimilar exposure	None
Controlled-substance status	Not a controlled substance

FDA labeling identifies terazosin hydrochloride as the active pharmaceutical ingredient in the capsule product and describes dose titration beginning at 1 mg.[1] DailyMed labeling for generic products shows that inactive ingredients can vary by manufacturer while maintaining the same active ingredient, strength, dosage form, and route of administration.[2]

When does terazosin lose exclusivity, and what is the Orange Book status?

Terazosin’s original small-molecule exclusivity and core patent protection expired many years ago. The product is therefore exposed to ordinary generic competition rather than a near-term patent cliff.

The Orange Book position for terazosin is commercially important because it determines whether an ANDA applicant must address listed patents with a Paragraph IV certification. Mature terazosin products generally do not present the type of active Orange Book patent barrier associated with recently approved branded drugs.[3]

Exclusivity issue	Commercial assessment
New chemical entity exclusivity	Expired
Original product patent estate	Expired or no longer commercially blocking
Current FDA exclusivity	No meaningful remaining exclusivity expected for standard immediate-release products
Orange Book patent risk	Low for conventional terazosin immediate-release products
Paragraph IV exposure	Limited unless a new formulation or method patent is listed
Generic launch constraint	Regulatory approval, manufacturing economics, and market access

The absence of a meaningful Orange Book barrier does not eliminate all intellectual-property risk. A company developing a differentiated formulation could encounter later patents covering a specific composition, manufacturing process, particle-size distribution, solid form, packaging system, or method of use. Those patents would need to be assessed independently from the expired originator estate.

What excipients are used in terazosin hydrochloride tablets and capsules?

Common excipient systems for immediate-release terazosin products include lactose, microcrystalline cellulose, starch, pregelatinized starch, povidone, croscarmellose sodium, colloidal silicon dioxide, talc, and magnesium stearate. Capsules may also include gelatin, titanium dioxide, and approved colorants.[1,2]

The preferred system depends on the manufacturing process and target product profile.

Excipient class	Candidate materials	Primary function	Key development issue
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Adds bulk and controls tablet mass	Low-dose content uniformity and compressibility
Binder	Povidone, hydroxypropyl cellulose, pregelatinized starch	Improves granule and tablet strength	Excess binder can slow dissolution
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes tablet breakup	Must be balanced against hardness and friability
Glidant	Colloidal silicon dioxide	Improves powder flow	Excess can reduce compactibility
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces tooling friction	Overlubrication may slow dissolution
Antiadherent	Talc	Limits sticking and picking	Can affect blend uniformity
Capsule shell	Gelatin or hypromellose	Unit-dose delivery	Moisture control and shell compatibility
Colorant	Iron oxides, titanium dioxide, approved dyes	Strength identification	Regulatory and visual differentiation

For a low-dose 1 mg product, the principal technical problem is not drug loading. It is uniform distribution of a small quantity of active ingredient across a relatively large excipient mass. Ordered mixing, geometric dilution, dry granulation, or wet granulation can be evaluated depending on powder flow and segregation behavior.

Which excipient strategy is best for a low-dose immediate-release product?

A robust commercial starting point is a direct-compression or dry-granulation platform using microcrystalline cellulose, lactose or mannitol, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate.

Direct-compression strategy

Direct compression has the lowest process complexity and can provide the lowest conversion cost when the active and excipient blend has suitable flow and compressibility.

A representative platform could use:

• Microcrystalline cellulose as the principal compressible diluent.
• Lactose monohydrate or mannitol as a secondary diluent.
• Crospovidone or croscarmellose sodium as the disintegrant.
• Colloidal silicon dioxide for flow enhancement.
• Magnesium stearate at a controlled concentration and lubrication time.

This approach is attractive for 2 mg, 5 mg, and 10 mg tablets. The 1 mg strength requires closer evaluation of content uniformity, segregation during transfer, and hopper residence time.

Dry-granulation strategy

Roller compaction can improve flow and reduce segregation without introducing water. It is useful when the active ingredient has poor flow, low bulk density, or unacceptable direct-compression behavior.

The main risks are:

• Loss of tabletability after compaction.
• Excessive fines generated during milling.
• Slower dissolution from dense granules.
• Increased process validation burden.

Dry granulation is especially relevant when moisture exposure creates a stability concern or when the active substance has limited wet-process robustness.

Wet-granulation strategy

Wet granulation can improve content uniformity and reduce dusting. Povidone, hydroxypropyl cellulose, or starch-based binders can be used. The process introduces additional risks, including residual moisture, hydrolysis or solid-state change, longer cycle time, and higher manufacturing cost.

Wet granulation is more defensible where the active substance has poor flow or where a high-capability manufacturing site already operates a validated aqueous granulation platform.

What formulation patents could protect a terazosin product?

A conventional terazosin immediate-release tablet is unlikely to support strong new composition-of-matter protection because the active ingredient and basic dosage form are mature. Patent value would more likely come from a narrow formulation or process claim.

Potential claim categories include:

1. A defined excipient ratio producing rapid disintegration and dissolution.
2. A low-dose blend with improved content uniformity.
3. A specific particle-size distribution for terazosin hydrochloride.
4. A controlled moisture or packaging system.
5. A taste-masked tablet or orally disintegrating dosage form.
6. A modified-release formulation.
7. A combination product with another antihypertensive or BPH therapy.
8. A process that reduces segregation, sticking, or degradation.
9. A specific solid-state form or polymorphic composition.
10. A formulation with improved tolerability through altered release or dose exposure.

The strongest practical protection would usually combine composition, process, and performance limitations. A claim directed only to using standard excipients such as lactose, starch, and magnesium stearate would have limited strength unless the formulation produced an unexpected and reproducible technical result.

How strong is the terazosin patent estate?

The legacy patent estate is weak as a barrier to ordinary generic entry. The commercial value of terazosin patents is concentrated in expired originator protection and does not provide a durable moat for standard immediate-release products.

Patent category	Expected strength for conventional product
Compound patent	None of practical current value
Standard immediate-release tablet	Low
Standard immediate-release capsule	Low
Specific low-dose uniformity formulation	Moderate if technically supported
Modified-release product	Potentially moderate to strong
Orally disintegrating product	Potentially moderate
Combination product	Potentially moderate
Manufacturing process	Narrow, dependent on claim scope and detectability
Packaging and moisture protection	Usually limited unless tied to unexpected stability results

A new entrant should not assume that an excipient substitution creates meaningful patent protection. Patentability will depend on novelty, non-obviousness, enablement, and evidence that the selected formulation solves a defined technical problem.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are more relevant than patent barriers for standard terazosin products.

The principal technical risks are:

• Low-dose content uniformity, particularly at 1 mg.
• Powder segregation during blending and transfer.
• Lubricant sensitivity.
• Tablet weight variability.
• Sticking or picking at higher compression forces.
• Moisture-mediated stability changes.
• Differences in dissolution caused by granule density or lubricant level.
• Color and strength-identification requirements.
• Cross-contamination controls in shared facilities.

A manufacturer can create commercial differentiation through a platform process that supports all strengths with minimal tooling changes. A common blend with proportional tablet weights may reduce development and validation costs, but dose proportionality must be demonstrated rather than assumed.

What commercial opportunities exist for terazosin hydrochloride anhydrous?

The most credible opportunities are operational and formulation-based.

Low-cost multisource supply

A reliable supplier can compete in hospital, retail, and mail-order channels by offering all major strengths, stable lead times, and consistent fill rates. Generic shortages, contract-manufacturing disruptions, and supplier consolidation can create openings even where market prices are low.

Capsule-to-tablet substitution

Tablets may provide lower packaging cost and simpler high-volume compression economics. Capsules can remain attractive for manufacturers seeking flexible color coding, encapsulation of a powder blend, or lower tablet-development complexity.

Orally disintegrating tablets

An orally disintegrating terazosin product could target patients with swallowing difficulty, although development must address dose uniformity, taste, friability, moisture sensitivity, and packaging. This would be a lifecycle product rather than a direct commodity substitute.

Modified-release delivery

Modified release could seek smoother exposure or reduced peak-related adverse effects. The commercial case is less certain because terazosin is already administered once daily in common regimens and competing alpha-1 blockers are established. A modified-release product would require clinical and regulatory justification beyond routine generic equivalence.

Combination therapy

Potential combinations with antihypertensive or BPH agents could simplify treatment, but combination development would face prescribing-pattern, dose-flexibility, clinical, and reimbursement constraints.

Regional and emerging-market supply

Markets with fragmented generic competition may reward a manufacturer that can supply 1 mg titration strengths and maintain consistent quality. Regulatory requirements, local bioequivalence standards, and price controls will determine attractiveness by country.

Which companies are challenging terazosin, and what is the generic landscape?

Terazosin is supplied by multiple generic manufacturers and distributors. The market is typically fragmented across ANDA holders, contract manufacturers, and private-label distributors rather than controlled by one dominant challenger.

Competition is based on:

• Approved strength coverage.
• Wholesale acquisition cost and contract pricing.
• Backorder performance.
• FDA inspection history.
• Ability to supply capsules and tablets.
• Packaging flexibility.
• Distributor and group-purchasing relationships.
• International registration status.

Because the product is mature, a new entrant needs a measurable cost or supply advantage. A conventional formulation without manufacturing differentiation is likely to compete primarily on price.

What patent litigation and Paragraph IV risks affect terazosin?

No major current litigation barrier is expected for the standard terazosin immediate-release market. Paragraph IV risk is most relevant if a new applicant targets a later-issued formulation or method-of-use patent listed for a specific product.

For a conventional ANDA, the principal legal work is likely to involve:

• Orange Book patent verification.
• Patent certification strategy.
• Freedom-to-operate review for excipient combinations.
• Assessment of process patents at the proposed manufacturing site.
• Review of trademark and trade-dress restrictions.
• Confirmation that labeling does not induce a patented use.

A formulation sponsor seeking exclusivity would need claims that are difficult to design around and easy to detect through product testing or manufacturing records.

How does terazosin compare with competing alpha-1 blockers?

Terazosin competes with doxazosin, tamsulosin, alfuzosin, and silodosin in BPH-related treatment, although these products differ in selectivity, dosing, tolerability, and market positioning.

Product	Main commercial distinction	Formulation opportunity
Terazosin	Low-cost, nonselective alpha-1 blocker; titration required	Low-dose uniformity, ODT, supply reliability
Doxazosin	Similar class with immediate- and modified-release products	Modified release and combination products
Tamsulosin	Uroselective positioning and broad BPH use	Controlled release and capsule supply
Alfuzosin	Extended-release BPH product	Release-control and food-effect management
Silodosin	Highly selective alpha-1A positioning	Capsule and tolerability-focused differentiation

Terazosin’s strongest commercial position is price and established clinical familiarity. Its weaker position is the need for titration and the availability of more uroselective alternatives.

What is the revenue exposure and launch outlook?

Revenue exposure is generally modest on a per-unit basis but can be meaningful at scale because the product is chronic-use therapy. A successful launch depends on recurring volume rather than premium pricing.

Launch scenario	Probability profile	Commercial result
Commodity immediate-release generic	Most accessible	Low margin, volume-dependent
Multi-strength tablet and capsule portfolio	Attractive	Better contracting position
ODT product	More complex	Potential premium if patient need is demonstrated
Modified-release product	High development burden	Possible differentiation, uncertain uptake
Combination product	Clinically and commercially complex	Niche opportunity
Regional supply agreement	Practical	Predictable volume with lower marketing cost

The best near-term strategy is a multi-strength immediate-release portfolio using a scalable excipient platform, supported by strong supply continuity and competitive cost of goods.

Key Takeaways

• Terazosin hydrochloride anhydrous is a mature generic active ingredient with no meaningful originator exclusivity barrier for conventional immediate-release products.
• The commercial opportunity lies in manufacturing efficiency, reliable supply, broad strength coverage, and formulation execution.
• Low-dose content uniformity is the central development issue, especially for the 1 mg strength.
• Direct compression is the preferred first-line platform when powder flow and compressibility are adequate.
• Dry granulation is a practical alternative when segregation or flow problems occur.
• Wet granulation may improve uniformity but adds cost, moisture exposure, and process complexity.
• Conventional excipient substitutions offer limited patent strength unless linked to unexpected technical performance.
• Orally disintegrating and modified-release products offer the clearest lifecycle opportunities but require stronger clinical and regulatory justification.
• Generic competition is likely to be driven by price, supply reliability, quality history, and strength availability rather than patent litigation.
• A commercially disciplined program should prioritize a four-strength immediate-release portfolio before pursuing differentiated delivery systems.

FAQs

Can terazosin hydrochloride anhydrous be formulated by direct compression?

Yes. Direct compression is feasible when the active-excipient blend achieves acceptable flow, segregation resistance, compressibility, content uniformity, and dissolution. The 1 mg strength requires the most extensive process characterization.

Which excipient is most important for terazosin content uniformity?

The diluent and blending system are more important than any single excipient. Microcrystalline cellulose, lactose, ordered mixing, geometric dilution, and controlled transfer conditions can improve distribution of the low-dose active ingredient.

Is anhydrous terazosin hydrochloride preferable to a hydrated form?

The selected solid form should be controlled by crystallinity, hygroscopicity, stability, dissolution, and regulatory specifications. An anhydrous designation alone does not establish superior manufacturability or bioequivalence.

Does terazosin have biosimilar risk?

No. Terazosin is a chemically synthesized small molecule, not a biologic. Competitive risk comes from generic ANDA products and potentially differentiated reformulations, not biosimilars.

Can an excipient strategy support a new terazosin patent?

Potentially, but only where the formulation produces a novel, non-obvious, and reproducible technical result. A routine combination of established diluents, binders, disintegrants, and lubricants is unlikely to create strong patent protection without supporting performance data.

References

1. U.S. Food and Drug Administration. (2023). Hytrin (terazosin hydrochloride) capsules prescribing information. FDA.
2. National Library of Medicine. (2024). DailyMed: Terazosin hydrochloride capsule labeling. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products. FDA.
5. International Council for Harmonisation. (2003). Q8(R2): Pharmaceutical development. ICH.